OcugenOCGN
About: Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Employees: 95
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
139% more call options, than puts
Call options by funds: $595K | Put options by funds: $249K
4% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 25
1% less funds holding
Funds holding: 115 [Q3] → 114 (-1) [Q4]
3% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 30
3.14% less ownership
Funds ownership: 27.68% [Q3] → 24.54% (-3.14%) [Q4]
8% less capital invested
Capital invested by funds: $79.1M [Q3] → $72.3M (-$6.72M) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Swayampakula Ramakanth 36% 1-year accuracy 65 / 180 met price target | 823%upside $7 | Buy Maintained | 12 May 2025 |
Chardan Capital Daniil Gataulin 17% 1-year accuracy 10 / 58 met price target | 823%upside $7 | Buy Maintained | 12 May 2025 |
Financial journalist opinion
Based on 4 articles about OCGN published over the past 30 days









